Tavexia Lifecare acquires 60% stake in Meyonex for ₹67.19 crore
- Tavexia Lifecare acquires 60% stake in Meyonex Pharmaceuticals for ₹67.19 crore
- Acquisition executed via cash subscription of fresh equity shares at ₹32 per share
- Company rebranded from Sattva Sukun Lifecare to focus on APIs, CDMO, and nutraceuticals
- Meyonex reported turnover decline from ₹13.32 crore in FY24 to ₹10.79 crore in FY25

*this image is generated using AI for illustrative purposes only.
Tavexia Lifecare Limited board approved the acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited for ₹67.19 crore. The transaction, executed through the subscription of fresh equity shares, aims to expand the company's presence in the pharmaceutical sector.
The board meeting held on October 7, 2026, reviewed and approved the valuation and due diligence reports for the target entity. Meyonex Pharmaceuticals is an unlisted public company incorporated in India. The acquisition involves subscribing to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share.
Strategic Rebranding and Business Expansion
The company has officially changed its name from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited. This rebranding signifies a structured realignment towards capitalizing on emerging opportunities across the pharmaceutical, wellness, and lifecare landscape. The company has altered its Main Object Clause under its Memorandum of Association to include:
- Active Pharmaceutical Ingredients (APIs) and Bulk Drugs.
- Finished Dosage Forms and Formulations, including tablets, capsules, and injectables.
- Contract Research and Manufacturing Services (CRAMS) and Contract Development and Manufacturing Organizations (CDMO).
- Nutraceuticals and Biotechnology segments.
The acquisition of Meyonex provides an immediate operational foothold with established manufacturing and commercial operations based in MIDC Tarapur, Maharashtra. This move is intended to leverage operational efficiencies and scale the revenue baseline through high-demand pharma product lines.
Transaction Structure and Consideration
The proposed investment will be made entirely in cash mode. Upon completion of the fresh issue and allotment, Tavexia Lifecare will hold a controlling stake of 60%, while existing shareholders will retain the remaining 40%. The total post-allotment paid-up equity share capital of Meyonex will stand at 3,49,95,300 shares.
| Particulars | Equity Shares | Percentage |
|---|---|---|
| Existing paid-up equity shares of Meyonex | 1,39,98,120 | 40.00% |
| Fresh equity shares allotted to Tavexia Lifecare | 2,09,97,180 | 60.00% |
| Total equity shares after allotment | 3,49,95,300 | 100.00% |
The consideration of ₹67,19,09,760 is subject to the execution of definitive agreements and fulfillment of applicable statutory and regulatory conditions. The transaction may be completed in one or more tranches.
Financing Arrangements
To finance the acquisition, the board approved in principle that the company may raise funds through various instruments, including equity shares, warrants, debentures, or debt securities. These funds can be raised on a preferential or rights issue basis, subject to subsequent board determinations regarding quantum, size, and timing based on market conditions.
What the Numbers Show
Meyonex Pharmaceuticals reported a turnover of ₹13.32 crore in FY24 and ₹10.79 crore in FY25, indicating a decline in revenue over the last reported financial year. Despite this contraction, Tavexia Lifecare has valued the 60% stake at ₹67.19 crore, implying a significant premium relative to the target's recent top-line performance. The deal structure relies on fresh capital infusion into Meyonex rather than purchasing existing shares, which will dilute current shareholders' percentage holding while providing liquidity to the target entity for operational expansion.
The acquisition is not related to promoter group companies and does not constitute a slump sale. Regulatory approvals remain pending as the company proceeds with definitive documentation.
Historical Stock Returns for Sattva Sukun Lifecare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +1.74% | -0.85% | +67.14% | +48.10% | 0.0% |
How will Tavexia Lifecare plan to reverse Meyonex Pharmaceuticals' declining revenue trend given the significant valuation premium paid?
What specific financing instruments and timelines does Tavexia intend to prioritize for raising the ₹67.19 crore, and how might this impact current shareholder dilution?
What are the expected regulatory approval timelines for this acquisition, and how could delays affect the integration of Meyonex's MIDC Tarapur operations?

































